ERBB2 and neoplasm: We previously demonstrated that combining RG7116 (anti-HER3 antibody) with RG7160 (anti-HER1 antibody) or pertuzumab (anti-HER2) achieved complete and long-lasting tumor growth inhibition in murine subcutaneous xenograft models in which tumor growth was driven by HER1 or HER2, respectively [22].